Advanced search
1 file | 599.36 KB

An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease : a case series

Author
Organization
Abstract
Background In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to alpha 4 beta 7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the alpha 4 beta 7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of alpha 4 beta 7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis. Nonetheless, the effect of vedolizumab on extraintestinal manifestations-and especially the joint-has not been reported so far. Case report A series of five patients with IBD who were treated with vedolizumab and promptly developed new onset or exacerbation of sacroiliitis or arthritis are reported. Conclusions Vedolizumab therapy does not seem to show any efficacy in and might even induce arthritis and/or sacroiliitis. However, larger cohort studies are needed to provide information on the prevalence, the evolution and underlying mechanism.
Keywords
CROHNS-DISEASE, MAINTENANCE THERAPY, ENDOTHELIAL LIGANDS, MUCOSAL, LEUKOCYTES, ULCERATIVE-COLITIS, T-CELLS, GUT, SPONDYLOARTHROPATHY, ADHESION, NATALIZUMAB

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 599.36 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Varkas, Gaëlle, Kristof Thevissen, G De Brabanter, Liesbet Van Praet, F Czul-gurdian, Heleen Cypers, JORIS DE KOCK, et al. 2017. “An Induction or Flare of Arthritis And/or Sacroiliitis by Vedolizumab in Inflammatory Bowel Disease : a Case Series.” Annals of the Rheumatic Diseases 76 (5): 878–881.
APA
Varkas, G., Thevissen, K., De Brabanter, G., Van Praet, L., Czul-gurdian, F., Cypers, H., DE KOCK, J., et al. (2017). An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease : a case series. ANNALS OF THE RHEUMATIC DISEASES, 76(5), 878–881.
Vancouver
1.
Varkas G, Thevissen K, De Brabanter G, Van Praet L, Czul-gurdian F, Cypers H, et al. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease : a case series. ANNALS OF THE RHEUMATIC DISEASES. 2017;76(5):878–81.
MLA
Varkas, Gaëlle, Kristof Thevissen, G De Brabanter, et al. “An Induction or Flare of Arthritis And/or Sacroiliitis by Vedolizumab in Inflammatory Bowel Disease : a Case Series.” ANNALS OF THE RHEUMATIC DISEASES 76.5 (2017): 878–881. Print.
@article{8521876,
  abstract     = {Background In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to alpha 4 beta 7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the alpha 4 beta 7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of alpha 4 beta 7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis. Nonetheless, the effect of vedolizumab on extraintestinal manifestations-and especially the joint-has not been reported so far. Case report A series of five patients with IBD who were treated with vedolizumab and promptly developed new onset or exacerbation of sacroiliitis or arthritis are reported. Conclusions Vedolizumab therapy does not seem to show any efficacy in and might even induce arthritis and/or sacroiliitis. However, larger cohort studies are needed to provide information on the prevalence, the evolution and underlying mechanism.},
  author       = {Varkas, Ga{\"e}lle and Thevissen, Kristof and De Brabanter, G and Van Praet, Liesbet and Czul-gurdian, F and Cypers, Heleen and DE KOCK, JORIS and Carron, Philippe and De Vos, Martine and Hindryckx, Pieter and Arts, J and Vanneuville, I and Schoenaers, P and Claerhout, B and Abreu, M and Van den Bosch, Filip and Elewaut, Dirk},
  issn         = {0003-4967},
  journal      = {ANNALS OF THE RHEUMATIC DISEASES},
  language     = {eng},
  number       = {5},
  pages        = {878--881},
  title        = {An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease : a case series},
  url          = {http://dx.doi.org/10.1136/annrheumdis-2016-210233},
  volume       = {76},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: